Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 36 Issue 1
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2018  >  36(1): 75-79

ZHAO Jing, CAO Hong, XING Jun-bo. The fingerprint analysis on Chuanshentong injection by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 137-139. doi: 10.3969/j.issn.1006-0111.2013.02.016
Citation: WEI Zewu, ZHANG Wenwen, MA Duoling, BI Juan, CHEN Jiexiu, YANG Yunyun. A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
shu

A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus

doi: 10.3969/j.issn.1006-0111.2018.01.016

  • Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

  • Received Date: 2017-02-20
  • Rev Recd Date: 2017-06-30
  • Objective To study the efficacy and adverse reactions for renal transplant patients conversed from cyclosporine A to tacrolimus. Methods The follow-up data of renal transplant patients conversed from cyclosporine A to tacrolimus were collected. The clinical therapeutic outcomes including drug induced diseases (DIDs) and acute rejection (AR) induced by cyclosporine A were analyzed during the first year after conversion with SPSS17.0 software. Results The levels of Scr and BUN were significantly decreased during the first year after conversion for renal transplant patients with CScr and AR (P<0.05 or P<0.01). The levels of direct bilirubin (DB) and total bilirubin (TB) were also significantly lowed (P<0.05 or P<0.01) during the first year for drug-induced liver injury (DILI) patients. The average level of ALT was significantly decreased in 12 months after conversion (P<0.05). The complications of gingival overgrowth (GO) stopped with the medication replacement. However, the fasting blood glucose (FBG) level increased significantly in 12 months after conversion (P<0.05). Conclusion For renal transplant patients suffered from AR or the serious DIDs induced by cyclosporine A, conversion from cyclosporine A to tacrolimus could be considered. However, it should be aware of the high blood glucose or the new diabetes caused by tacrolimus.
  • [1] Halloran PF. Immunosuppressive drugs for kidney transplantation[J]. N Engl J Med, 2004,351(26):2715-2729.
    [2] Krämer BK, Montagnino G, Krüger B, et al. Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation:7-year observational results[J]. Transpl Int, 2016,29(3):307-314.
    [3] Ateyya H. Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin[J]. Int Immunopharmacol, 2015,28(1):571-577.
    [4] Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy[J]. N Engl J Med, 2003, 349(24):2326-2333.
    [5] Gau CH, Tu HP, Chin YT, et al. Can chlorhexidine mouthwash twice daily ameliorate cyclosporine-induced gingival overgrowth?[J]. J Formos Med Assoc, 2013,112(3):131-137.
    [6] Wadei HM, Textor SC. Hypertension in the kidney transplant recipient[J]. Transplant Rev (Orlando), 2010,24(3):105-120.
    [7] Rezzani R. Cyclosporine A and adverse effects on organs:histochemical studies[J]. Prog Histochem Cytochem,2004,39(2):85-128.
    [8] Kamel M, Kadian M, Srinivas T, et al. Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine[J].World J Transplant,2016, 6(4):697-702.
    [9] Franke GH, Trampenau C, Reimer J, et al. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation[J]. Transplant Proc, 2006,38(5):1293-1294.
    [10] Videla CO. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy[J]. Transplant Proc, 2009,41(6):2659-2663.
    [11] Margreiter R, Pohanka E, Sparacino V, et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects[J]. Transpl Int, 2005,18(7):816-823.
    [12] 黄晓宁,陈小娟,李勇. 肾移植术后患者应用他克莫司与环孢素A发生急性排斥反应的Meta分析[J].中国医院用药评价与分析,2016,16(5):636-639.
    [13] Tao Y, Hu L, Li S, et al. Tranilast prevents the progression of chronic cyclosporine nephrotoxicity through regulation of transforming growth factor β/Smad pathways[J].Transplant Proc,2011,43(5):1985-1988.
    [14] Seeland S, Török M, Kettiger H, et al. A cell-based, multiparametric sensor approach characterises drug-induced cytotoxicity in human liver HepG2 cells[J]. Toxicol In Vitro, 2013,27(3):1109-1120.
    [15] Cond SAP, Bastos MG, Vieira BJ, et al. Down-regulation of transforming growth factor beta-2 expression is associated with the reduction of cyclosporin induced gingival overgrowth in rats treated with roxithromycin:an experimental study[J]. BMC Oral Health,2009,9(1):33.
    [16] Al-Hamilly NS, Radwan LR, Abdul-Rahman M, et al. Biological roles of KGF, CTGF and TGF-β in cyclosporine-A-and phenytoin-induced gingival overgrowth:A comparative experimental animal study.[J]. Arch Oral Biol,2016,66:38-43.
    [17] 余爱华,辛华雯,吴笑春,等.环孢素和他克莫司对肾移植后发生糖尿病的影响研究[J]. 中国药师, 2011,14(4):521-523.
    [18] Sinangil A, Celik V, Barlas S, et al. New-onset diabetes after kidney transplantation and pretransplant hypomagnesemia[J]. Prog Transplant, 2016, 26(1):55-61.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-040Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 85.9 %FULLTEXT: 85.9 %META: 12.8 %META: 12.8 %PDF: 1.3 %PDF: 1.3 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 28.6 %其他: 28.6 %Singapore: 0.2 %Singapore: 0.2 %United States: 0.2 %United States: 0.2 %上海: 2.1 %上海: 2.1 %北京: 11.8 %北京: 11.8 %十堰: 0.2 %十堰: 0.2 %南京: 0.2 %南京: 0.2 %密蘇里城: 0.4 %密蘇里城: 0.4 %成都: 0.6 %成都: 0.6 %杭州: 0.6 %杭州: 0.6 %武汉: 0.2 %武汉: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沧州: 0.2 %沧州: 0.2 %盐城: 0.2 %盐城: 0.2 %聊城: 0.4 %聊城: 0.4 %芒廷维尤: 13.9 %芒廷维尤: 13.9 %西宁: 37.4 %西宁: 37.4 %西安: 0.2 %西安: 0.2 %运城: 0.4 %运城: 0.4 %郑州: 0.2 %郑州: 0.2 %鄂州: 0.2 %鄂州: 0.2 %长沙: 0.2 %长沙: 0.2 %长治: 0.2 %长治: 0.2 %黄冈: 1.1 %黄冈: 1.1 %其他SingaporeUnited States上海北京十堰南京密蘇里城成都杭州武汉沈阳沧州盐城聊城芒廷维尤西宁西安运城郑州鄂州长沙长治黄冈Highcharts.com

  • Cited by

    Periodical cited type(8)

    1. 林新，王诗宝，何焕清，李钦艳，钟莹莹，陈逸湘，肖自添，凌宏通，曹斌，林苑云. 广东省梅州市紫灵芝产业现状与发展对策. 中国食用菌. 2023(04): 115-119 .
    2. 张碧云，陆敏. 灵芝在慢性萎缩性胃炎治疗中的应用进展. 云南中医中药杂志. 2022(09): 80-83 .
    3. 李亚晗，刘佳琳，王天添，刘玟妍，孙丽媛，李明成. 灵芝多糖抗肿瘤免疫调节机制的研究进展. 中国免疫学杂志. 2021(04): 511-514 .
    4. 赵玲. 灵芝多糖在运动员抗脂质过氧化中的作用. 中国食用菌. 2021(02): 75-79 .
    5. 田义敏，周欣，赵超，陈华国，龚小见. 中药有效成分抗胃癌作用机制的研究进展. 中国中药杂志. 2020(15): 3584-3593 .
    6. 王雪妍，周伏忠，向凌云，陈晓飞，宁萌，刁文涛. 灵芝免疫调节蛋白LZ-8及云芝免疫调节蛋白FIP-tvc对几种癌细胞系的抑制活性检测. 河南科学. 2019(06): 914-918 .
    7. 刘玲，李奇璋，周选围，王玉亮. 重组黑芝免疫调节蛋白对小鼠巨噬细胞RAW264.7向M1型分化的影响. 食品科学. 2019(23): 170-175 .
    8. 何嘉烽，吴小勇，尹辉，李文治，何文江. 水溶性灵芝粉的制备及其免疫调节活性评价. 广东药科大学学报. 2018(03): 288-292 .

    Other cited types(5)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(4003) PDF downloads(930) Cited by(13)

Related
Proportional views

A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus

doi: 10.3969/j.issn.1006-0111.2018.01.016
  • Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China
  • Received Date: 2017-02-20
  • Rev Recd Date: 2017-06-30

Abstract: Objective To study the efficacy and adverse reactions for renal transplant patients conversed from cyclosporine A to tacrolimus. Methods The follow-up data of renal transplant patients conversed from cyclosporine A to tacrolimus were collected. The clinical therapeutic outcomes including drug induced diseases (DIDs) and acute rejection (AR) induced by cyclosporine A were analyzed during the first year after conversion with SPSS17.0 software. Results The levels of Scr and BUN were significantly decreased during the first year after conversion for renal transplant patients with CScr and AR (P<0.05 or P<0.01). The levels of direct bilirubin (DB) and total bilirubin (TB) were also significantly lowed (P<0.05 or P<0.01) during the first year for drug-induced liver injury (DILI) patients. The average level of ALT was significantly decreased in 12 months after conversion (P<0.05). The complications of gingival overgrowth (GO) stopped with the medication replacement. However, the fasting blood glucose (FBG) level increased significantly in 12 months after conversion (P<0.05). Conclusion For renal transplant patients suffered from AR or the serious DIDs induced by cyclosporine A, conversion from cyclosporine A to tacrolimus could be considered. However, it should be aware of the high blood glucose or the new diabetes caused by tacrolimus.

ZHAO Jing, CAO Hong, XING Jun-bo. The fingerprint analysis on Chuanshentong injection by HPLC[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 137-139. doi: 10.3969/j.issn.1006-0111.2013.02.016
Citation: WEI Zewu, ZHANG Wenwen, MA Duoling, BI Juan, CHEN Jiexiu, YANG Yunyun. A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
shu

    HTML

Reference (18)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return